about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

With pipeline set­backs mount­ing, Unit­ed snares pri­or­i­ty vouch­er for in­haled for­mu­la­tion of PAH med Ty­va­so

5 years ago
Pharma
FDA+

Af­ter mul­ti­ple set­backs, Bris­tol My­ers scut­tles Op­di­vo pro­gram for brain tu­mor pa­tients af­ter fail­ing to pro­long ...

5 years ago
R&D
Pharma

Dana-Far­ber backed Neo­morph hunts 'un­drug­gable' pro­teins with new round of in­vestor cash for hires, de­vel­op­ment

5 years ago
Financing

Pe­ter Thiel joins fund­ing round for pep­tide drug play­er in lat­est swing at emerg­ing biotech mar­ket

5 years ago
People
Financing

Patrick Soon-Sh­iong merges trou­bled 'moon shot' Nan­tK­west and cell ther­a­py play Im­mu­ni­ty­Bio in late-stage ex­pan­sion

5 years ago
Deals
Cell/Gene Tx

Glax­o­SmithK­line joins So­sei's who's-who list of clients with glob­al li­cens­ing pact for IBD small mol­e­cules

5 years ago
Deals

Glax­o­SmithK­line makes big down pay­ment on biotech tar­get­ing 'syn­thet­ic vi­a­bil­i­ty' with start­up fund­ing, pipeline ...

5 years ago
Financing
Discovery

Glax­o­SmithK­line, Vir look to suc­ceed where Lil­ly failed with NIH an­ti­body study in hos­pi­tal­ized Covid-19 pa­tients

5 years ago
R&D
Coronavirus

Af­ter los­ing race for first to mar­ket in lu­pus nephri­tis, Au­rinia taps Ot­su­ka for vo­closporin li­cens­ing pact abroad

5 years ago
Deals

Glax­o­SmithK­line's Benlysta earns first FDA ap­proval for lu­pus nephri­tis as com­peti­tors wait in the wings

5 years ago
Pharma
FDA+

Macro­Gen­ics scores first FDA ap­proval with breast can­cer med Mar­gen­za in third-line pa­tients

5 years ago
Pharma
FDA+

No­var­tis sets eyes on new­ly-ac­quired Alex­ion with break­through tag for rare dis­ease hope­ful ip­ta­co­pan

5 years ago
Pharma
FDA+

No­var­tis earns ad­com­m's vote of sup­port in come­back FDA re­view for En­tresto in sought-af­ter heart fail­ure pa­tients

5 years ago
Pharma
FDA+

Months in­to boom­ing acute mi­graine launch, Bio­haven chas­es pre­ven­tion with oral CGRP med Nurtec ODT

5 years ago
R&D

No­var­tis rais­es the temp on Eylea ri­val­ry with head-to-head tri­al win for Beovu in di­a­bet­ic mac­u­lar ede­ma

5 years ago
R&D

Eli Lil­ly picks up gene ther­a­py play­er Pre­vail in deal worth $1B+, mak­ing good on bolt-on pledge from ear­li­er this ...

5 years ago
Deals
Cell/Gene Tx

At­tor­neys gen­er­al ask HHS to pun­ish 340B pro­gram bilk­ers — but phar­ma claims it's fight­ing 'waste and abuse'

5 years ago
Pharma

Mass­Bio head Cough­lin set to step down af­ter over­see­ing mas­sive bio­phar­ma ex­pan­sion in the state dur­ing 13-year ...

5 years ago
People
R&D

Vi­a­tris plans across-the-board cuts that could en­dan­ger 9,000 work­ers, 15 plants in post-merg­er re­struc­tur­ing scheme

5 years ago
Pharma

De­spite flop­ping piv­otal tri­al, No­var­tis' En­tresto will face ad­comm fir­ing line for holy grail heart fail­ure pa­tients

5 years ago
Pharma
FDA+

Faze Med­i­cines launch­es with $81M Se­ries A, Al­ny­lam vet head­ing sci­ence in play at bio­mol­e­c­u­lar con­den­sates

5 years ago
Financing
Startups

Look­ing to solve pub­lic health crises through dis­cov­ery, Gates Foun­da­tion taps AI firm Ex­sci­en­tia to look for an­swers

5 years ago
AI
Discovery

No­var­tis' CDK4/6 med Kisqali, firm­ly the sales un­der­dog against Pfiz­er's Ibrance, drops big OS da­ta

5 years ago
R&D
Pharma

Ab­b­Vie chas­es its next gold­en goose in a post-Hu­mi­ra fu­ture with new ul­cer­a­tive col­i­tis da­ta for Rin­voq

5 years ago
R&D
Pharma
First page Previous page 1819202122 Next page Last page
A service from the Financial Times